BMY logo

Bristol-Myers Squibb Company

BMY
Healthcare|Drug Manufacturers - General|US
$62.14
-0.99 (-1.57%)
DCF Value
$239.82
Graham Number
$34.15
Cash / Share
$6.16

About

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.

Stock Price

+33.3%(1Y)
1M
+4.3%
3M
-4.0%
6M
+10.6%
YTD
+15.2%
1Y
+31.5%
3Y
+18.5%
5Y
+4.6%

Pipeline Summary

104 total trials
27
Phase 1
35
Phase 2
25
Phase 3
7
Phase 4
Completed: 47Unknown: 9Recruiting: 23Not Yet Recruiting: 3Terminated: 10Withdrawn: 4Active: 8

Active Trials (31)

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06121843Multiple Myeloma
Phase 1Recruiting
Enrollment: 187 participants
A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants
NCT07204418Healthy Volunteers
Phase 1Recruiting
Enrollment: 56 participants
A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
NCT06788652Mantle Cell Lymphoma (MCL)
Recruiting
Enrollment: 300 participants
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
NCT06126224Psychosis Associated With Alzheimer's Disease
Phase 3Recruiting
Enrollment: 500 participants
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
NCT05511363Psychosis Associated With Alzheimer's Disease
Phase 3Recruiting
Enrollment: 410 participants

BioScore

7/10
Buy

Key Facts

Market Cap$127.02B
Employees32,500 (-5% YoY)
CEOChristopher Boerner
IPO DateJun 1, 1972
Beta0.23
52-Week Range$45.27 – $68.64
Avg Volume11,340,716
ExchangeNYSE
Websitebms.com

Ownership

Float99.7%
Shares Outstanding2044.1M

Recent Insider Trades

Haller Julia ASELL
Nov 5, 20263,800 shares @ $63.31
Lenkowsky AdamOPTION EX.
Nov 3, 20267,522 shares
Lenkowsky AdamTAX W/H
Nov 3, 20263,848 shares @ $61.71
Lenkowsky AdamOPTION EX.
Nov 3, 20267,522 shares
BOERNER CHRISTOPHER S.J
Nov 1, 2026406 shares

Peers

ABBVAbbVie Inc.
$514.78B
AMGNAmgen Inc.
$248.92B
AZNAstraZeneca PLC
$289.14B
GILDGilead Sciences, Inc.
$207.00B
GSKGSK plc
$102.02B
JNJJohnson & Johnson
$664.95B
LLYEli Lilly and Company
$1273.77B
MRKMerck & Co., Inc.
$361.96B
Data last updated: Nov 9, 2026, 04:00 AM